Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Sarcoma × Rosiglitazone × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Thyroid Neoplasms 1 Thyroid Cancer, Papillary 1 Squamous Cell Carcinoma of Head and Neck 1 Sezary Syndrome 1 Sarcoma 1 Pituitary Neoplasms 1 Mycosis Fungoides 1 Melanoma 1 Lymphoma, T-Cell, Cutaneous 1 Liposarcoma 1 Leukoplakia, Oral 1 Head and Neck Neoplasms 1 Central Nervous System Neoplasms 1 Carcinoma, Hepatocellular 1 Adenocarcinoma, Follicular 1 Adenocarcinoma Of Esophagus 1

Interventions

Doxorubicin 56 Ifosfamide 35 Gemcitabine 26 Radiotherapy 24 Filgrastim 23 Cyclophosphamide 23 Docetaxel 18 Vincristine 16 Etoposide 16 pazopanib 15 Nivolumab 15 pembrolizumab 14 Trabectedin 14 Magnetic Resonance Spectroscopy 13 apatinib 12 Cisplatin 12 Sirolimus 10 Irinotecan 10 Carboplatin 10 Temozolomide 9 Surgical Procedures, Operative 9 Sorafenib 9 Ipilimumab 9 Bevacizumab 9 anlotinib 8 Specimen Handling 8 Dactinomycin 8 X-Rays 7 Topotecan 7 Paclitaxel 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00004180 2023-06-26

Rosiglitazone in Treating Patients With Liposarcoma

Dana-Farber Cancer Institute

Phase 2 Completed

Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡